Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Provide Administrative Guidance in 23 Cases of Ethical Drug Advertising Activities
The Ministry of Health, Labor and Welfare (MHLW) announced the results of a project to monitor ethical drug advertising activities conducted in FY2016. Of 39 cases of advertising activities suspected to be inappropriate that were reported during the three-month survey…
To read the full story
Related Article
- Govt Should Screen Drug Promotion Material, Scope of Information Provided: HSC Member
June 8, 2018
- MHLW Finds 67 Suspected Violations in Sales Reps’ Advertising Activities; Cites Need for Official Reporting System
May 18, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Still Pondering Steps to Ensure Proper Sales Activities by Drug Reps
February 28, 2018
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…